Arcutis Biotherapeutics, Inc. (ARQT)
Largest Insider Buys in Sector
ARQT Stock Price History Chart
ARQT Stock Performance
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; …
Insider Activity of Arcutis Biotherapeutics, Inc.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $247,554 and sold $3.24M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $34.27M and sold $3.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $1.6M. Watanabe Todd Franklin (See Remarks) — $21,250. Matsuda Masaru (See Remark) — $18,543.
The last purchase of 1,093 shares for transaction amount of $7,767 was made by Edwards Larry Todd (See Remarks) on 2024‑11‑30.
List of Insider Buy and Sell Transactions, Arcutis Biotherapeutics, Inc.
| 2024-12-02 | Sale | director | 10,000 0.0086% | $12.51 | $125,133 | +1.85% | ||
| 2024-11-30 | See Remarks | 2,038 0.0009% | $7.11 | $14,482 | 0.00% | |||
| 2024-11-30 | See Remarks | 1,657 0.0008% | $7.11 | $11,775 | 0.00% | |||
| 2024-11-30 | See Remarks | 1,093 0.0005% | $7.11 | $7,767 | 0.00% | |||
| 2024-11-22 | Sale | See Remarks | 16,023 0.0136% | $10.14 | $162,515 | +24.06% | ||
| 2024-11-19 | Sale | See Remarks | 1,775 0.0015% | $9.68 | $17,190 | +4.70% | ||
| 2024-11-15 | Sale | See Remarks | 100 <0.0001% | $10.03 | $1,003 | +34.02% | ||
| 2024-11-14 | Sale | See Remarks | 18,377 0.0161% | $10.29 | $189,182 | 0.00% | ||
| 2024-11-11 | Sale | director | 8,687 0.0074% | $10.85 | $94,238 | +13.56% | ||
| 2024-11-04 | Sale | See Remarks | 13,871 0.0117% | $8.68 | $120,459 | +40.48% | ||
| 2024-11-04 | Sale | See Remarks | 15,441 0.0131% | $8.68 | $134,093 | +40.48% | ||
| 2024-11-04 | Sale | See Remarks | 5,015 0.0042% | $8.68 | $43,551 | +40.48% | ||
| 2024-11-01 | Sale | director | 10,000 0.0085% | $8.65 | $86,541 | +38.18% | ||
| 2024-10-02 | Sale | SVP Chief Commercial Officer | 3,725 0.0035% | $10.01 | $37,295 | +0.10% | ||
| 2024-10-01 | Sale | director | 10,000 0.0086% | $9.26 | $92,616 | +7.17% | ||
| 2024-09-24 | Sale | Chief Financial Officer | 11,626 0.0098% | $9.48 | $110,264 | -3.42% | ||
| 2024-09-03 | Sale | director | 10,000 0.0088% | $10.77 | $107,695 | -2.43% | ||
| 2024-08-19 | Sale | See Remarks | 1,728 0.0014% | $8.29 | $14,318 | +19.13% | ||
| 2024-08-02 | Sale | See Remarks | 14,487 0.0122% | $9.02 | $130,648 | +10.05% | ||
| 2024-08-02 | Sale | See Remarks | 13,206 0.0111% | $9.02 | $119,106 | +10.05% |
Insider Historical Profitability
| Heron Patrick J | director | 8785284 7.5059% | $14.99 | 3 | 0 | <0.0001% |
| Watanabe Todd Franklin | See Remarks | 838430 0.7163% | $14.99 | 3 | 43 | +6.79% |
| Matsuda Masaru | See Remarks | 187030 0.1598% | $14.99 | 2 | 11 | |
| Edwards Larry Todd | See Remarks | 137728 0.1177% | $14.99 | 1 | 2 | |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.4879% | $14.99 | 2 | 0 | +5.03% |
Institutional Investor Ownership
| JENNISON ASSOCIATES LLC | $120.67M | 10.52 | 12.18M | +34.31% | +$30.82M | 0.08 | |
| Frazier Life Sciences Management L P | $87.06M | 7.59 | 8.79M | +0.24% | +$208,625.32 | 3.93 | |
| State Street | $87.05M | 7.59 | 8.78M | +475.99% | +$71.94M | <0.01 | |
| Suvretta Capital Management, LLC | $78.06M | 6.81 | 7.88M | -7.03% | -$5.9M | 3.3 | |
| Helm Capital Management LLC | $74.42M | 6.49 | 7.51M | +13.03% | +$8.58M | 2.2 |